In urothelial bladder cancer (UBC), the prevalence of EGFR overexpression ranges from 25% to 50%, with a higher frequency observed in muscle-invasive bladder cancer (MIBC) compared to non-muscle-invasive bladder cancer (non-MIBC) [29,30]. The gene discussed is EGFR; the disease is bladder transitional cell carcinoma.